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Population Pharmacokinetics of Amoxicillin in
Term Neonates Undergoing Moderate
Hypothermia
YA Bijleveld1, RAA Matho^t1, JH van der Lee3, F Groenendaal4, PH Dijk5, A van Heijst6, SHP Simons7,
KP Dijkman8, HLM van Straaten9, M Rijken10, IA Zonnenberg11, F Cools12, A Zecic13,
DHGM Nuytemans14, AH van Kaam2, TR de Haan2 for the PharmaCool Study Group
The pharmacokinetics (PK) of amoxicillin in asphyxiated newborns undergoingmoderate hypothermia were quantified
using prospective data (N5 125). The population PK was described by a 2-compartment model with a priori birthweight
(BW) based allometric scaling. Significant correlations were observed between clearance (Cl) and postnatal age (PNA), ges-
tational age (GA), body temperature (TEMP), and urine output (UO). For a typical patient with GA 40weeks, BW 3,000 g, 2
days PNA (i.e., TEMP 33.58C), and normal UO, Cl was 0.26 L/h (interindividual variability (IIV) 41.9%) and volume of distribu-
tion of the central compartment was 0.34 L/kg (IIV of 114.6%). For this patient, Cl increased to 0.41 L/h at PNA 5 days and
TEMP 37.08C. The respective contributions of both covariates were 23% and 27%. Based onMonte Carlo simulations we
recommend 50 and 75mg/kg/24h amoxicillin in three doses for patients with GA 36–37 and 38–42 weeks, respectively.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 To date, there are no data on the effect of moderate hypo-
thermia on the pharmacokinetics (PK) of amoxicillin in term
neonates. Only few studies have been performed to evaluate the
PK of this antibiotic in noncooled (pre)term neonates.
WHAT QUESTION DID THIS STUDY ADDRESS?
 To our knowledge, this is the ﬁrst prospective study evaluat-
ing and describing the PK of amoxicillin during all phases of
controlled hypothermia in newborns, e.g., the hypothermic,
rewarming, and normothermic phases.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 A description of the PK properties of amoxicillin in term
newborns with hypoxic-ischemic encephalopathy (HIE) due to
perinatal asphyxia receiving hypothermia treatment. Gestational
age (GA), postnatal age (PNA), urine output, and body temper-
ature were signiﬁcant covariates on amoxicillin clearance (Cl).
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Based on the newly developed PK-model, we advise an
amoxicillin dosing regimen of 50 or 75 mg/kg/24h in three
doses for patients with GA 36 or GA 38–42 weeks, respectively.
Term neonates who experience a severe hypoxic-ischemic insult
during birth and develop encephalopathy are treated with hypo-
thermia.1,2 This improves long-term outcomes and reduces mortal-
ity rates.2–9 These patients may suffer from early-onset sepsis with
Streptococcus agalactiae (incidence rate 0.43% (95% conﬁdence
interval (CI) 0.37–0.49)), while Listeria monocytogenes should also
be considered.10 Because asphyxia due to infection is difﬁcult to
distinguish from asphyxia without infection, antibiotics, such as
amoxicillin, are frequently used.11 For efﬁcacy, as a surrogate
marker, the time that the nonprotein-bound concentration in
blood exceeds the minimum inhibitory concentration (T>MIC)
should be at least 40–50% in these patients.12 Although b-lactam
antibiotics such as amoxicillin are considered safe due to the wide
therapeutic range, excessive accumulation can lead to the develop-
ment of adverse drug events, such as seizures and crystalluria.13
Despite the widespread use of amoxicillin in (pre)term neo-
nates, the literature describing its pharmacokinetic (PK) proper-
ties in these patients is sparse and mostly concerns small patient
numbers or preterm infants,14–16 while studies in hypothermic
neonates are lacking altogether. As hypothermic treatment can
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alter the PK of certain drugs,17 studying its potential effect on
amoxicillin is important.
We present the results of a prospective observational cohort
study in asphyxiated newborns treated with moderate hypother-
mia and describe the population PK of amoxicillin in order to, if
necessary, propose a more rational dosing regimen.
RESULTS
Patients
In total, 125 out of 187 newborns included in the PharmaCool
Study11 received amoxicillin during moderate hypothermia. Demo-
graphic and clinical characteristics, and samples drawn of the total-,
index-, and validation datasets are presented in Table 1. Twenty-
seven (22%) patients died during the study period. However, in all
cases this was not due to a persistent uncontrollable infection, but
to multiorgan failure (MOF) or withdrawal of medical intensive
care treatment in patients with an adverse prognosis. In total, 23
samples (2%) were below the limit of quantiﬁcation. In Supple-
mentary Figure 1 the observed concentrations vs. the time after
dose are shown. No serious adverse drugs events were recorded.
Pharmacokinetic model building
With the index dataset (N 5 80) a two-compartment model
parameterized in terms of clearance (Cl), volume of distribution
of the central (Vc) and peripheral (Vp) compartment, and
intercompartmental clearance (Q) was preferred to a one- and
three-compartment model. Parameters were normalized a priori
to a body weight of 70 kg using the 3/4 rule.18 The allometric
exponents could not be estimated, as this resulted in unstable
models (nonconvergence in the iterative process), probably due
to the small range of weight in the population.
Residual variability of the log-transformed data was described
with an additive error model. Interindividual variability (IIV)
could be estimated for Cl and Vc and was correlated (r 5 0.49).
Although the objective function value (OFV) decreased signiﬁ-
cantly by adding interoccasion variability (IOV), h-shrinkage was
640%, reducing the power of IPRED and IWRES plots to detect
model and residual model misspeciﬁcation, respectively. Also,
models were unstable (eigen values (EV) >1,000). Therefore,
IOV was not included in the model. The structural model had
an OFV of –675.6.
In the univariate covariate analysis postnatal age (PNA), body
temperature (TEMP), urine output (UO), gestational age (GA),
and inotropic comedication were identiﬁed as signiﬁcant covari-
ates on Cl, with DOFV of –435.1, –402.2, –163.4, –26.0, and
–8.8 points, respectively. Postmenstrual age (PMA) also was a sig-
niﬁcant covariate on Cl (DOFV –266.9). However, as PNA alone
gave a higher drop in OFV than PMA, PNA and GA were imple-
mented as separate covariates on Cl (P < 0.001). No relationship








GA (weeks)b 40 (36-42) 40 (36-42) 40 (37-42)
BW (grams)b 3340 (2090-5070) 3400 (2090-4835) 3310 (2295-5070)
Male 74 (59.2)c 49 (61.3)c 25 (56)c
PNA (days)d 5 (2-5) 5 (2-5) 5 (2-5)
SCr (lmol/L)e,f 55 (25-239) 53 (25-239) 57 (25-183)
Urine output (ml/kg/h)e,f 2.34 (0.04-10.00) 2.33 (0.04-5.40) 2.40 (0.10-10.00)
ASAT (U/L)e,f 83 (19-9179) 83 (22-1860) 84 (19-9719)
ALAT (U/L)e,f 38 (3-2631) 38 (3-518) 39 (5-2631)
MOFe 80 (64)c 53 (67)c 27 (60)c
Inotropic medicatione 78 (62)c 51 (63.8)c 27 (60)c
Thompson scoreb 9 (3-19) 9 (3-19) 9 (3-19)
Samples total (N) during study 1280 841 439
Samples (N) per patient during study 10 (1-16) 10 (1-16) 11 (1-15)
Samples total (N) during hypothermic phase 882 575 307
Samples (N) per patient during hypothermic phase 8 (1-9) 8 (1-9) 8 (1-9)
Samples (N) during rewarming phaseg 124 78 46
Samples total (N) during normothermic phase 274 188 86
Samples (N) per patient during normothermic phase 3 (1-6) 4 (1-6) 3 (1-6)
aData are presented as median (minimum-maximum) unless stated otherwise. bParameter measured at admittance. cData presented as n (%). dParameter measured at
end of study period. eParameter measured throughout study period. fNormal values for neonates PNA<7 days: urine output: 1-3 ml/kg/h, SCr: 35-80 lmol/L, ASAT:
<125 U/L and ALAT: <65U/L. gDuring rewarming samples were available as residual material of other laboratory monitoring. GA, gestational age; BW, birth weight; PNA,
postnatal age; SCr, serum creatinine; MOF, multiorgan failure; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.
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between Cl and gender, aspartate aminotransferase (ASAT), ala-
nine aminotransferase (ALAT), serum creatinine (SCr), urea, 1-h
postnatal blood gas pH, Thompson score, or MOF was detected.
Maturation models as covariates on Cl did not improve the PK
model. Univariate analysis indicated that SCr, ASAT, and
Thompson score were signiﬁcant covariates for Vc, resulting in a
drop in OFV of 38.8, 38.8, and 4.2 points, respectively. After the
forward inclusion and backward deletion inotropic comedication
on Cl and the covariates on Vc were discarded, while the other
above-mentioned signiﬁcant covariates were retained. The h-and e-
shrinkage were <20%, rendering the EBE-based diagnostics useful
for model evaluation.19 Final parameter estimates are shown in
Table 2. For a typical patient with GA 40 weeks, birthweight
(BW) 3,000 g, 2 days PNA (i.e., TEMP 33.58C), and normal UO
(2 ml/kg/h), Cl increased from 0.26 l/h to 0.41 L/h at PNA 5 days
and TEMP 37.08C. The increase of PNA and TEMP contributed
23% and 27%, respectively, to the rise of Cl. CL was 81% higher in
patients with GA 42 weeks when compared to GA 36 weeks. An
increase of UO from 0.5 to 6 ml/kg/h augmented CL by 22%.
Model evaluation and validation
Table 2 gives the results of the bootstrap analysis of the ﬁnal
model developed with the index dataset (N 5 80). As the results
were in agreement with those of the ﬁnal model developed with
the index dataset, the ﬁnal model estimates are considered reli-
able. The goodness-of-ﬁt (GOF) plots and normalized prediction
distribution error (NPDE) plots are shown in Figure 1. These
indicate that there was no major bias in the population compo-
nent of the ﬁnal model and that an appropriate structural model
was found for most individuals. No ill-conditioning was found in
the ﬁnal model (EV 160). The IIV of Cl and CWRES vs. covari-
ates and visual predictive checks (VPC) plots can be found in
Supplementary Figures 2 and 3.
The results of the mean prediction error (MPE) and root
mean squared prediction error (RMSE) calculated with the vali-
dation dataset (N 5 45) are shown in Table 3. The bias and
imprecision for concentrations <100 mg/L was acceptable. In
Supplementary Figure 4 the GOF and NPDE plots of the vali-
dation of the PK model built with the index dataset are shown.
The population PK parameters of the ﬁnal model built with
the total dataset (N5 125) were comparable to those of the ﬁnal
model built with the index dataset (Table 2). The results of the
bootstrap analysis were in agreement with those of the ﬁnal
model developed with the total dataset. Variability between Cl
and Vc was correlated with r 5 0.48. The h- and e-shrinkage
were <20%. No ill-conditioning was found in the ﬁnal model
(EV 446). In Supplementary Figures 3 and 5 the GOF, NPDE
and VPC plots are shown.
Table 2 Parameter estimation of final pharmacokinetic models with final model associated bootstraps
Parameters
Model-building dataset (N5 80) Total dataset (N5 125)














OFV –1229.3 – – – – –1814.0 – – – –
Cl (L h-1/70 kg) 3.03 5 3.06 2.74 3.35 2.92 4 2.94 2.71 3.21
HCL_PNA 0.20 19 0.21 0.13 0.28 0.22 12 0.23 0.16 0.29
HCL_TEMP 2.70 13 2.66 1.82 3.42 2.43 13 2.36 1.65 3.01
HCL_ URINE OUTPUT 0.11 13 0.11 0.3 0.19 0.08 6 0.08 0.02 0.16
HCL_GA 5.12 19 5.08 3.32 7.17 3.86 21 3.96 2.18 5.60
Vc (L/70 kg) 27.4 15 28.5 19.7 38.3 24.1 4 27.2 20.3 34.4
Q (L h-1/70kg) 8.8 14 8.30 6.30 11.37 7.93 12 7.46 5.61 9.70
Vp (L/70 kg) 24.0 9 23.3 19.2 27.8 24.1 4 23.1 20.3 26.1
Additive error 0.19 6 0.19 0.17 0.22 0.20 5 0.19 0.17 0.22
IIV Cl (%) 42.1 10 41.1 32.6 52.6 41.9 9 41.6 34.1 49.8
IIV Vc (%) 108.7 14 99.1 67.7 159.5 114.6 11 106.2 77.1 153.5
IIV additive residual
error (%)
49.2 13 49.4 35.6 65.0 46.8 10 47.1 36.3 58.8
Final model:
TVCl 5 2.92 x (BW/70)0.75 x (PNA/2.35)0.22 x (TEMP/33.5) 2.43x (URINE OUTPUT/ 2.99)0.08 x (GA/280)3.86
TVVc 5 24.1 x (BW/70)1
TVQ 5 7.93 x (BW/70)0.75
TVVp 5 24.1 x (BW/70)1.
#Median estimates. OFV, Objective Function Value; Cl, clearance; PNA, postnatal age (days); TEMP, body temperature (8C); URINE OUTPUT, daily urine output (ml/kg/h);
GA, gestational age (days); CV, coefficient of variation; CI, confidence interval; Vc, volume of distribution of the central compartment; Q, intercompartmental clearance; Vp,
volume of distribution of the peripheral compartment; IIV, interindividual variability; TV, typical value; BW, birth weight.
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Simulations
The results of the simulations of 100 mg/kg/24h in three doses and
75 mg/kg/24h in three doses for patients with GA 36–42 weeks
stratiﬁed for UO are presented in Figure 2. The ﬁrst dosage regimen
can result in very high concentrations, whereas the second dosage
regimen will sufﬁce for patients with GA 38 weeks irrespective of
UO or TEMP as the T>MIC (1 mg/L) is 100% in all cases, while
there are no toxic (>140 mg/L) levels. However, taking into account
the underprediction of the PK model at concentrations >100 mg/
L, this regimen might lead to too high concentrations in patients
with GA 36 weeks. For this group a regimen of 50 mg/kg/24h in
three doses (Figure 2) will lead to adequate concentrations. In Sup-
plementary Table 1 the simulated trough and peak concentrations
of these and other dosage regimens are displayed.
Figure 1 Upper panel: Goodness-of-fit plots of observations (mg/L) vs. the population predicted (left) and individual predicted (right) concentrations
(unit: mg/L). Middle panel: Conditional weighted residuals (CWRES) vs. time after dose (left; unit: h) and population predicted concentrations (right) of
the final model built with index dataset (n 5 80). The solid line represents the line of identity. Lower panel: quantile-quantile (QQ)-plot of the metrics
based on observations (black dots) vs. the theoretical N(0,1) distribution (dashed line) (left) and histogram of the normalized prediction distribution error
(NPDE) distribution vs. the theoretical N(0,1) distribution (dashed line) (right).
















Bias (mg/L) (95% CI) –5.3 (–7.5 to –3.0) –56.6 (–73.5 to –39.8) –13.0 (–17.2 to –8.7) 2.2 (0.3–4.0) 1.8 (0.6–3.0)
Imprecision (mg/L2) (95% CI) 24.7 (19.9–28.7) 72.6 (50.8 –89.2) 25.5 (22.1–28.5) 14.3 (12.5–16.0) 5.5 (2.1–7.5)
Bias, mean prediction error (MPE); Imprecision, root mean squared prediction error (RMSE). Larger values of RMSE indicate larger imprecision.
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Figure 2 Model-based predicted median concentration–time profiles (solid line) and the 5th and 95th percentile intervals (dashed lines) for patients with
varying gestational ages (GA), body weights (BW) (GA 36 weeks (BW 2,260 g), 38 weeks (BW 2,380 g), 40 weeks (BW 2,950 g), and 42 weeks (BW
4,720 g), respectively), and varying urine output (UO) (0.5, 2.0 and 6.0 ml/kg/h) receiving 50 mg/kg every 12 h and 25 mg/kg amoxicillin every 8 h. For
patients with GA of 36 weeks dosages of 50 mg/kg in four doses and 50 mg/kg in three doses are also shown. The solid lines at 1 and 140 mg/L depict
the minimum and maximum target levels. The periods from 0–72 h, 72–96 h, and >96 h reflect the hypothermic, the rewarming, and the normothermic
phase, respectively. [Color figure can be viewed at cpt-journal.com]
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DISCUSSION
To our knowledge this is the ﬁrst prospective study evaluating the
PK characteristics of amoxicillin in a cohort of asphyxiated term
infants with hypoxic ischemic encephalopathy (HIE) undergoing
moderate hypothermia.
The PK properties of amoxicillin were described by a two-
compartment model with a priori BW based allometric scaling
and PNA, TEMP, GA, and UO being factors of inﬂuence on Cl.
For a typical patient (GA 40 weeks, BW 3,000 g, 2 days PNA
(TEMP 33.58C), and normal UO (2 ml/kg/h)) Cl was 0.26 L/h
(IIV 41.9%) increasing to 0.41 l/h at 5 days PNA (TEMP 378C);
the corresponding values expressed per kg weight (linear) are 0.09
and 0.14 L/h/kg, respectively. Two studies on the PK of amoxi-
cillin in nonhypothermic term neonates found a Cl of 0.10 L/
kg/h, which is similar to our ﬁndings.14,20 If the typical patient
was polyuric (UO 6 ml/kg/h), Cl increased by 22% compared to
oliguria (UO 0.5 ml/kg/h). This is not surprising as, although in
adults amoxicillin is mainly excreted by glomerular ﬁltration and
tubular excretion,21,22 in neonates tubular secretion is very inefﬁ-
cient and glomerular ﬁltration is believed to be the major path-
way for elimination.15,23 Furthermore, Cl increased with
increasing GA and BW. PNA and GA are known predictors of
glomerular ﬁltration rate (GFR) maturation and drug Cl.15,24,25
TEMP being an independent covariate is very interesting. It can
be debated that PNA (reﬂecting GFR maturation and drug Cl)
and TEMP are correlated and a distinction in the effect of both
on Cl is not possible. However, a relationship in time is lacking
(PNA increases linearly, while TEMP is constant during the ﬁrst
72 h, where after it gradually increases to normothermia). Also,
the individual effects on Cl were signiﬁcant (27% increase if
TEMP rises from 33.5–37.08C and 23% increase from PNA 2–5
days). A meta-analysis of several randomized controlled trials
studying the effect of moderate hypothermia in neonates showed
no signiﬁcant difference in the incidence of renal impairment
during cooling compared with standard NICU care.7 Neverthe-
less, animal studies demonstrated that systemic mild hypothermia
may reduce the GFR in the immature kidney.26 Furthermore, in
a previous study we found that cooling delayed normalization of
gentamicin Cl, an antibiotic also mainly eliminated by glomerular
ﬁltration.27
For Vc no signiﬁcant covariate-parameters relationship was
identiﬁed besides BW. In our patient population the Vc was
0.34 L/kg (IIV of 114.6%) for a typical patient (GA 40 weeks,
BW 3,000 g). The Vd of amoxicillin is increased in neonates, as
this drug is water-soluble and thus mainly distributed in the rel-
atively larger extracellular volume compared to adults.28 In non-
asphyxiated (pre)term neonates values of (0.41–0.68 l/kg) have
been found.12,14,20 However, these patients were not comparable
to our population due to lower GA or larger PNA. A large
IIV of V and Cl is also found in (pre)term nonasphyxiated
neonates.15,16,20,25,29
The predictive performance of the ﬁnal model developed with
the index dataset showed a small statistically signiﬁcant bias of
–5.3 mg/L amoxicillin (imprecision 24.7 mg/L2 (Table 3)). This
is mainly due to the large bias in concentrations of >100 mg/L
(–56.6 mg/L and 72.6 mg/L2, respectively). In the index dataset
only 53 samples (6.3%) had a concentration >100 mg/L, which
could explain this lower performance. Notwithstanding, the
Figure 2 Continued.
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NPDE plots showed that the model performed well in describ-
ing the individual data of the validation dataset. The underpre-
diction of concentrations >100 mg/L have been taken into
account in the proposed dosing regimen. Simulations based on
our ﬁnal PK model demonstrated that 50 mg/kg/day and 75
mg/kg/day amoxicillin in three doses (GA 36–37 and 38–42
weeks, respectively) for 7 days results in adequate concentrations
(T>MIC 100%) in the case of infections with Streptococcus aga-
lactiae and Listeria monocytogenes (MIC 0.25 mg/L and 1.0 mg/
L, respectively), while avoiding nontoxic peak levels (<140 mg/
L) regardless of variation in the signiﬁcant covariates on Cl (GA,
PNA, TEMP, UO)14,30,31 This is due to the wide therapeutic
range of amoxicillin. The proposed dosage regimen is compara-
ble to the dosage regimen of 20 mg/kg every 8 h advised for
patients with GA>34 weeks by Pullen et al.14 based on their PK
analysis and simulations of amoxicillin in nonasphyxiated term
neonates. They, however, maintained a higher target for effectiv-
ity due to the MIC of 8 mg/L for Enterococcus species and spe-
cies belonging to the enterobacteriacae as causative agents of
bacteremia.
As can be seen from the simulated trough levels (Figure 2 and
Supplementary Table 1) of lower amoxicillin dosage regimens
(e.g., 12.5 mg/kg/day in two doses) than the ones proposed
would result in adequate concentrations. It is likely that lower
doses may provide an optimal balance between efﬁcacy and safety.
However, ﬁnding the lowest dose for these patients was not an
aim of this study. We have merely evaluated the current practice
and described the PK of amoxicillin in these patients, as this
information was lacking. If so desired, the effectivity of lower
dosage regimens than the ones advised should be studied in pro-
spective dose-ﬁnding studies.
We chose a maximum total concentration of 140 mg/L amoxi-
cillin based on scarce literature of two case reports in adults
receiving ampicillin i.v. with only one peak level and one mid-
dose level measured.14,31 Although a limited number of neuro-
toxic adverse events (including seizure, encephalopathy, and
tremor) related to amoxicillin treatment have been reported, the
role of epileptogenic drugs, such as penicillins, may be underesti-
mated in neonates, as seizure detection in these patients is chal-
lenging.32 It was striking that, despite the advice of the Dutch
Pediatric Formulary (75 mg/kg/day amoxicillin in three doses in
term neonates <1 week PNA and 2,000 g BW),33 62%
patients received a median dose of 50 (range 28–100) mg/kg
every 12 h, which could result in toxic peak levels, as shown by
our simulations.
Due to ethical reasons it was not possible to prospectively com-
pare our results with nonhypothermic HIE patients. In our opin-
ion, comparison with a historic control group would not lead to
a better evaluation, as the clinical characteristics of historic con-
trols would not be comparable to our cohort due to many
changes in intensive care treatment and admission criteria after
the introduction of the hypothermia protocol. Also, an adequate
historic control group is not available, as data were not collected
as meticulously as in the current study before introduction of the
hypothermia protocol.
We did not measure the free concentration of amoxicillin.
Because the amount of protein binding of amoxicillin in neonates
is low (about 10%),34 this was considered negligible in determin-
ing our target concentration. Also, the effect of hypothermia on
protein binding of amoxicillin was not evaluated. Although fur-
ther investigation is warranted, this would be most beneﬁcial in
drugs that are highly protein-bound. The effect of a possible
decrease of protein binding of amoxicillin is expected to have lit-
tle clinical relevance.
Patients with GA <36 weeks were not included as, due to a
lack of sufﬁcient evidence, in the Netherlands and Belgium pre-
term infants are not treated with moderate hypothermia.
In conclusion, this study shows that the PK proﬁle of amoxicil-
lin in asphyxiated term neonates treated with moderate hypother-
mia was best described by a two-compartment model with PNA,
TEMP, GA, and UO being primary factors of inﬂuence on Cl.
Based on simulations, we recommend 50 or 75 mg/kg/24h




Data were collected from a multicenter prospective observational cohort
study conducted in 10 Dutch and 2 Belgian NICUs (the “PharmaCool
Study,”11 November 2010 until October 2014).
According to national protocol,35 term newborns were cooled within
6 h after birth to a core TEMP of 33.58C for 72 h if they met the crite-
ria of perinatal asphyxia and ensuing encephalopathy.11 Thereafter,
patients were slowly (0.48C/h) rewarmed to normothermia (378C). All
newborns undergoing moderate hypothermia were eligible for inclusion.
Exclusion criteria were congenital hepatic or renal pathology, absence of
central venous or arterial access for blood sampling, or lacking parental
informed consent. One participating center also excluded patients with
other serious congenital malformations or chromosomal abnormalities.
The study was approved by the Institutional Review Board of each par-
ticipating center.
Data and sample collection
Data on GA, BW, gender, cause of the perinatal asphyxia, extent and
duration of resuscitation, ventilator, and/or inotropic support, Thomp-
son score, comedication, mean daily UO (ml/kg/h, collected via indwell-
ing urine catheter), SCr, urea, ASAT, and ALAT were collected.
Amoxicillin was prescribed in a dosage according to the local practice
and administered as an i.v. bolus. One participating center administered
amoxicillin/clavulanic acid as standard treatment. Dosing information
and sampling times were recorded in a digital case report form. The dos-
age regimens are shown in Table 4. Despite the advised amoxicillin dos-
age published in the Dutch Pediatric Formulary,33 the range of dosing
regimens was large. As most infants were born in referring peripheral
hospitals the information about the ﬁrst amoxicillin dose was largely
unknown. A standard dose of 25 mg/kg was presumed in those cases.
Blood samples for PK analysis of amoxicillin were collected: 6, 3, and
5 samples on days 2, 3 (hypothermia), and day 5 (normothermia),
respectively.
The amoxicillin concentration was analyzed by zwitterion hydrophilic
interaction chromatography coupled to tandem mass spectrometry (con-
centration range 0.5–40 mg/L) in only 10 lL of plasma. The accuracy
and imprecision at the lowest, middle, and upper limits of quantiﬁcation
were 105% and 10%, 102% and 6.5%, and 98% and <1.6%, respectively.
Samples containing >40 mg/L amoxicillin were diluted 10 times and
reanalyzed.
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Pharmacokinetic modeling
Data were analyzed using the ﬁrst-order conditional estimation (FOCE)
method with interaction option in the nonlinear mixed-effects modeling
software NONMEM v. 7.2 (Globomax, Hanover, MD). Tools like R
(https://www.r-project.org/, open-source, S-based statistical software, v.
0.98.945), XPose,36 and PsN37 were used to visualize and evaluate the
models. The model-building process was performed in a stepwise fashion.
Structural model
First, a random selection (every fourth patient upon inclusion) was made of
80 patients (the index dataset) from the total of 125 patients. The concen-
tration data were log-transformed and one-, two-, and three-compartment
models were ﬁtted to the data. PK parameters were estimated as Cl, Vc, Vp,
and Q. For all parameters IIV and covariance were tested assuming a log-
normal distribution.38 To account for variability in PK parameters due to
the varying sizes of individual children, BW was included a priori in all
model parameters using an allometric power model in which the parameter
values were standardized to a body weight of 70 kg.
P5u13 ðBW=70ÞPWR (1)
where u1 is the typical value of the parameter P and PWR is the allome-
tric scaling parameter, which was ﬁxed at values of 0.75 and 1.0 for CL
and V, respectively.18 PWR was also estimated to evaluate if this would
result in a better ﬁt. Residual variability was estimated using an additive
error model. IOV was estimated with an occasion being a 24-h period.
The likelihood ratio test was used to evaluate statistical signiﬁcance
between nested models where a reduction in the OFV 3.9 points was
considered statistically signiﬁcant (P < 0.05 based on v2 distribution,
df 5 1). Also, GOF plots (PRED or IPRED vs. observations, individual
conditional weighted residuals (iWRES) vs. IPRED, and CWRES vs.
time), the total number of parameters, visual improvement of individual
plots, correlation matrix, conﬁdence intervals of parameter estimates, ill-
conditioning, and h- and e-shrinkage were assessed.19,38
Covariate model
Continuous covariates were tested separately in the model, using a power
function equation:
P5u13 ðCOV=COVmedianÞu2 (2)
where u1 is the typical value of the parameter P in a patient with the
median covariate value (COV) and u2 is the fractional change in P with
each unit of deviation from the median COV. Continuous covariates
tested were PNA, PMA, GA, TEMP, ASAT, ALAT, SCr, urea, Thomp-
son score, and UO. PMA was calculated by adding GA (in days) to
PNA (in days). Categorical covariates were implemented in the model
according to the following equation:
P5u13 ðu2ÞCOV (3)
where u1 is the typical value of the parameter P and u2 is the fractional
difference in P between categories. For categorical dichotomous data
(gender, MOF: yes/no, and inotropic comedication: yes/no) the value of
the covariate was set to 0 for the reference classiﬁcation and 1 for the
other classiﬁcation. MOF was considered to be present if a patient had
renal or liver function failure as described by Shah et al.39
Maturation models (sigmoid Emax functions and sigmoid hyperbolic
functions) were tested to evaluate the effect of maturation of organ func-
tion on the parameter estimates.18,40
In a stepwise fashion the signiﬁcance of covariates was tested.38 In the
forward inclusion a P value of < 0.05 was applied (a decrease in OFV of
at least 3.9 points, df 5 1), while a more stringent P value of <0.001
was used in the backward deletion (a decrease in the OFV of at least
10.3 points, df 5 1). To rule out bias across the covariates, plots of IIV
and CWRES vs. the signiﬁcant covariates were made.
Model evaluation and simulations
Model evaluation and validation. To evaluate parameter precision and
model stability a nonstratiﬁed nonparametric bootstrap analysis was per-
formed using the PsN Toolkit37 in which the index dataset was
resampled 1,000 times to produce a new dataset the size of the original
but with a different combination of individuals. The parameter estimates
obtained with the bootstrap (median values and 95% CI) were compared
to the parameter estimates of the ﬁnal PK model.
The NPDE method was used to evaluate the predictive properties of
the model. To do so, the index dataset was simulated 2,000 times in
NONMEM using Monte-Carlo simulations in which the random effects
were included. If the model adequately describes the simulated data, the
NPDE is expected to follow a N(0,1) distribution. A histogram and
quantile-quantile (QQ) plot of the NPDE distribution were used to
evaluate the ﬁnal model.41 VPCs were performed to evaluate how well
the ﬁnal model describes the central tendency and variability of the
observed data (simulation properties). The simulated median and 95%
prediction intervals, derived from 1,000 datasets simulated from the
developed model using the original dataset as a template, were compared
to the ones from the observed data. The simulated and observed medians
and 95% percentiles correspond closely if the model adequately describes
the data.
The validation dataset contained the data of the remaining 45
patients. The population PK parameters obtained with the index dataset
were ﬁxed at the ﬁnal parameters estimated and PRED were calculated
using the same sampling times as measured in the validation dataset
using the NONMEM MAXEVAL 5 0 command.19,38 Also, the GOF
plots were evaluated. To evaluate the predictive performance of the ﬁnal












in which N is the number of pairs of true with predicted values and PEj
is the relative prediction error for each pair (PRED-observed concentra-
tion). The RMSE is then calculated as the square root of the MSE
Table 4 Observed dosage regimens of patients receiving amoxi-
cillin (N 5 125)
Total daily dosea 300 (60-740) mg / 91 (25-199) mg/kg
Duration of therapya 4 (1-6) days
N (%) Observed dosage regimena
77 (61.6%) 50 (28-100) mg/kg b.i.d
41 (32.8%) 25 (23-28) mg/kg t.i.d.
1 (0.8%) 49 mg/kg q.i.d.
4 (3.2%) 30 (25-50) mg/kg single dose
1 (0.8%) 3 doses of 26 mg/kg q.i.d. followed
by 26 mg/kg q.d.
1 (0.8%) 5 doses of 38 mg/kg b.i.d. followed
by 27 mg/kg t.i.d.
aMedian (range), unless stated otherwise. b.i.d., bis in die, two times a day; t.i.d.,
ter in die, three times a day; q.i.d., quater in die, four times a day; q.d., quaque die,
once a day.
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(mean squared error). The NPDE method was also used to evaluate the
predictive properties of the ﬁnal model developed with the index dataset.
Lastly, the model-building process, model evaluation, and internal val-
idation were repeated as described above but with the data of all 125
patients that received amoxicillin (total dataset) to ensure that the same
PK model would be developed as based on a random selection of the
patients.
Simulations. To examine the optimal dosing regimen, Monte Carlo
simulations (n 5 1,000) using the ﬁnal model were performed in NON-
MEM on a selection of patients from the original database (GA 36
weeks (BW 2,260 g), 38 weeks (BW 2,380 g), 40 weeks (BW 2,950 g),
and 42 weeks (BW 4,720 g)). The amoxicillin dosage regimens most fre-
quently used in the patient population (100 mg/kg/24h in two doses
and 75 mg/kg/24h in 3 doses) were simulated. For patients with GA 36
weeks a lower dosage regimen (50 mg/kg/24 h in three doses) was evalu-
ated. Although in clinical practice UO can vary within patients, UO was
ﬁxed at 0.5 ml/kg/h (oliguria), 2 ml/kg/h (normal UO), or 6 ml/kg/h
(polyuria) for graphical display. TEMP was set at 33.58C during 0–72 h
PNA, where after it increased with 0.48C/h to normothermia (378C).
The median (including 5th and 95th percentiles) of the simulated con-
centrations (n5 1,000, samples drawn every hour) and simulated trough
and peak concentrations (including interquartile range) were computed.
The MIC of value ranges of amoxicillin for Streptococcus agalactiae
and Listeria monocytogenes, the most important neonatal pathogens caus-
ing early-onset sepsis in the Netherlands, are 0.25 mg/L and 1.0 mg/L,
respectively.30 As amoxicillin plasma protein binding in neonates is low
(about 10%),34 we assumed that the simulated amoxicillin concentra-
tions must be above 1 mg/L for at least 40–50% of the dosing interval
to ascertain bacteriologic efﬁcacy.12
Additional Supporting Information may be found in the online version of
this article.
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